← Leaderboards
John M Timmerman
University Of California Los Angeles
$2,572,153
Attributed
$3,098,059
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $570.8K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$3,098,059 · 6
By mechanism
R01$1,531,509 · 1
T32$1,051,812 · 1
R21$505,257 · 1
M01$9,481 · 3
Top collaborators
- John P Chute4 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Dennis J Hartigan-O'Connor$32,284,293
- Judith S. Currier$525,401,794
- Paul Wender$20,449,594
- Koki Morizono$5,593,709
- Sherie L Morrison$12,725,119
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceB-Cell Nonhodgkins LymphomaTumorAntibodiesImmuneT-LymphocyteRelapseCd8b1 GeneMonoclonal AntibodiesClinical ResearchImmunotherapyBinding (Molecular Function)AgonistAntigen BindingB-Cell LymphomasAntibody -Dependent Cell CytotoxicityCombined Modality TherapyBase SequenceCell Culture TechniquesAcademic TrainingCell LineCellsChemistryCd4 Positive T Lymphocytes
Grant awards (14)
Academic Training in Hematology$250,154
T32 · FY2017 · HL · contact PI
Academic Training in Hematology$276,817
T32 · FY2016 · HL · contact PI
Academic Training in Hematology$254,716
T32 · FY2015 · HL · contact PI
Antibody-CpG conjugates for the treatment of B cell lymphoma$300,665
R01 · FY2014 · CA · contact PI
Academic Training in Hematology$270,125
T32 · FY2014 · HL · contact PI
Antibody-CpG conjugates for the treatment of B cell lymphoma$291,366
R01 · FY2013 · CA · contact PI
Antibody-CpG conjugates for the treatment of B cell lymphoma$309,964
R01 · FY2012 · CA · contact PI
Antibody-CpG conjugates for the treatment of B cell lymphoma$309,964
R01 · FY2011 · CA · contact PI
Antibody-CpG conjugates for the treatment of B cell lymphoma$319,550
R01 · FY2010 · CA · contact PI
PHASE I/II STUDY OF ANTI-CTLA-4 MONOCLONAL ANTIBODY (MDX-010) IN FOLLICULAR N$1,069
M01 · FY2008 · RR · contact PI
PHASE I/II STUDY OF ANTI-CTLA-4 MONOCLONAL ANTIBODY (MDX-010) IN FOLLICULAR N$4,809
M01 · FY2007 · RR · contact PI
PHASE I/II STUDY OF ANTI-CTLA-4 MONOCLONAL ANTIBODY (MDX-010) IN FOLLICULAR N$3,603
M01 · FY2006 · RR · contact PI
Anti-CTLA-4 Monoclonal Antibody Therapy for Lymphoma$253,380
R21 · FY2005 · CA
Anti-CTLA-4 Monoclonal Antibody Therapy for Lymphoma$251,877
R21 · FY2004 · CA